Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) rose another 3% as it confirmed it is in discussions with stakeholders about the supply of natural gas to consumers in south central Alaska.
In a short statement, Pantheon added that there is no guarantee that these discussions will lead to definitive agreements and the company's planning basis continues to rely upon the reinjection of all hydrocarbons that cannot be exported through the Trans-Alaska Pipeline System (TAPS) main oil line.
ImmuPharma PLC (AIM:IMM)'s shares surged 35% on Wednesday, buoyed by promising updates on financial and operational fronts, including active discussions with potential commercial partners for its assets.
The company said it had funds enough to meet its immediate needs, while commercial deals for its drug candidates would also help.
Galliford Try Holdings PLC (LSE:GFRD) said it will meet its sustainable growth targets ahead of plan as it provided an optimistic assessment of prospects alongside a strong first-half financial and operational showing.
The construction group exited the period sitting on a £3.7 billion order book (up £200 million on the same time last year), adding that has excellent visibility over future business with 98% and 83% of this year's and next's revenues secured.
ImmuPharma PLC (AIM:IMM) said it is in 'active discussions' with potential commercial partners as it updated on its financial and operational performance.
Investors were told that it has funds to meet its immediate requirements, while the revenues for licensing deals for the non-US rights to P140, its lead asset, its CIDP programme and anti-infective, BioAMB, will help meet its longer cash needs.